ANTIARRHYTHMIC AND HEMODYNAMIC-EFFECTS OF ALLAPININE DURING ITS COURSE THERAPY IN PATIENTS WITH CIRCULATORY FAILURE

The antiarrhythmic effects of allapinine were studied in 57 patients w ith chronic circulatory failure (CCF) and cardiac arrhythmias by emplo ying 48-hour Holter monitoring. Allapinine was found to suppress prema ture ventricular contraction, group premature ventricular contraction and 'runs' of ventricular tachycardia by 82.5, 88.6, and 93.1 %, respe ctively. The antiarrhythmic activity of the agent was more pronounced in patients with coronary heart disease, Stages I-IIA CCF and left ven tricular ejection fraction greater than 40%. In addition, in Stages I- IIA CCF allapinine increased myocardial contractility and left ventric ular ejection fraction, whereas in Stages IIB-III CCF it showed a slig ht cardiodepressive effect. Thus, when given in the course therapy in patients with CCF, allapinine has a high antiarrhythmic activity and, to a lesser extent, affects central hemodynamics.